ACE Biosciences and Aeras Global TB Vaccine Foundation enter tubercolosis vaccine collaboration
ACE BioSciences A/S and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, US, have entered a collaboration whereby ACE BioSciences will support characterization of second-generation BCGbased tuberculosis (TB) vaccines under development by Aeras.
The current TB vaccine, BCG, does not provide good protection against pulmonary TB in adults or children. Aeras is working on a range of second-generation BCG vaccines with the aim of enhancing the protection they afford and introducing other improvements such as patient-friendly delivery options. As part of this programme, Aeras has developed secondgeneration recombinant BCG strains where specific proteins have been introduced or the expression of existing proteins has been enhanced.
Under the terms of the agreement, Aeras has approached ACE BioSciences to apply its analytical tools to identify and characterise the proteins in these recombinant BCGbased TB vaccines. This research will enable Aeras to understand and refine its developmental vaccines and it will underpin the manufacture of promising candidates. Financial details of the collaboration were not disclosed.
Other news from the department business & finance
